Skip to main content

Schlieren, Zürich, Switzerland  ·  12 October 2021

Rejuveron Life Sciences AG (‘Rejuveron’), a Zürich-based biotechnology company developing therapies to promote healthy aging, today announced that it will ultimately acquire a majority shareholding in Rejuvenate Biomed NV (‘Rejuvenate’), a Belgium-based biomedical company developing novel combination drugs for age-related diseases.

The EUR 15.7 million Series B funding, led by Rejuveron and Luxembourg-based Vesalius Biocapital, is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).

Rejuvenate aims to increase people’s healthy years of life by translating the science behind what keeps cells vital and resilient into human therapeutics. The company has developed a proprietary in silico screening platform that uses an approach based on artificial intelligence and network biology to investigate dysregulated pathways in aging. With this platform, Rejuvenate is able to evaluate if safe, marketed treatments can be used as synergistic drug combinations to impact upon these pathways, maintaining our natural cellular resilience and postponing the onset of certain age-related diseases.

Rejuvenate’s lead drug candidate RJx-01 is a novel, small molecule, combination product identified using the company’s in silico platform. RJx-01 is being developed for the treatment of acute and chronic sarcopenia, a muscle disease defined by the loss of muscle strength, quality, and mass. There is a huge unmet medical need in sarcopenia: the disease affects 50% of elderly and rehabilitation patients, and there is no approved therapy on the market.

In vivo studies with RJx-01 have demonstrated the treatment’s ability to improve muscle mass and strength, as well as beneficial effects in the prevention and treatment of other age-related diseases. Rejuvenate’s Series B will now be used to advance RJx-01 through a Belgian Phase Ib clinical trial and an international multicenter Phase IIb trial. The funds will also go towards exploring the treatment’s potential in other diseases, as well as further developing the company’s in silico screening platform and pipeline of other drug candidates.

Dr. Matthias Steger, PhD, MBA, CEO of Rejuveron said: “Over the past four years, the Rejuvenate team has demonstrated that its approach can be used to develop new patent-protected combination drugs based on known prescription medicines. This platform has resulted in a promising first drug candidate, with the wider application being to deliver therapeutics with a meaningful impact on the treatment and prevention of multiple age-related diseases by tackling their root causes. This strikes right at the heart of Rejuveron’s purpose: making therapies happen for people to stay healthier for longer.”

Dr. Ann Beliën, PhD, Founder and CEO of Rejuvenate said: “This investment is more to us than a financial deal: it is the result of Vesalius Biocapital’s unrelenting belief in what we do, and the backing of Rejuveron, a company with which we share a fully aligned vision and complementary expertise. This investment will result in an intense collaboration between the Rejuveron and Rejuvenate teams, lifting us all to the next level. Becoming a clinical-stage company is a key milestone for us, and we could not have reached this point without the dedication of our excellent team and the continued support of our investors. We look forward to a future where products from our platform help people live healthier lives.”

Mr. Stéphane Verdood, MBA, MSc, Managing Partner at Vesalius Biocapital III said: “Vesalius Biocapital III has supported Rejuvenate since the company’s inception. Its excellent scientific basis, sound clinical approach and strong management team convinced us to invest at an early stage of development. The current round will allow Rejuvenate to reach proof of concept in an underserved medical area, and we are pleased that Rejuveron shares this drive.”

About Rejuveron

Rejuveron Life Sciences AG is a fully integrated biotechnology platform company that invests in people and ideas to develop therapies and technologies to improve healthy aging and prolong lifespan. Its team of experienced drug discovery and development experts provide start-up coaching and funding to entrepreneurial scientists. Rejuveron has state-of-the-art incubator laboratory facilities in Zürich’s Bio-Technopark in Schlieren.

For more information, please visit
Follow us on LinkedIn

About Rejuvenate Biomed

Rejuvenate Biomed is an independent Belgian biomedical company established in October 2017 by Ann Beliën, PhD, after nearly two decades of experience with Janssen Pharmaceutical companies of Johnson and Johnson. The company is developing safe, proprietary, combination drugs that delay or prevent the onset of multiple age-related diseases, with a focus on the intersection between fundamental aging mechanisms and chronic conditions.

Rejuvenate Biomed is a resident company of Johnson & Johnson Innovation, JLABS, a premier life sciences incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.

For more information, please visit:

For Rejuveron

At the company  ·  +41 79 500 9824
Charles Consultants  ·  +44 7968 726585

About Rejuveron

Rejuveron is a clinical-stage biotechnology company creating therapies to improve healthy aging. Its experienced drug discovery and development team applies a deep understanding of the biology of aging, alongside technological advances in biopharmaceutical R&D, to progress a new generation of medicines that will help people to age better and live longer.

Through its programs, each uniquely focused on preventing, repairing, or reversing the hallmarks of aging, Rejuveron is advancing a therapeutic pipeline that ranges from drug discovery to the clinic. Rejuveron’s business model is to create or acquire innovative programs, each being held within a wholly owned or majority-owned company.

The current portfolio is diversified across modalities, stages, as well as aging hallmarks, and includes a revolutionary small molecule approach to regenerate endogenous stem cell, currently in a Phase 1/2a in the USA in retinitis pigmentosa patients; a novel drug combination therapy for sarcopenia in a Phase 1b human trial.

Rejuveron has headquarters and state-of-the-art laboratories in Switzerland’s biotech hub in Bio-Technopark Schlieren, Zürich with Abu Dhabi operations in the process of being set up. Its current portfolio includes: Endogena Therapeutics (Switzerland, USA & Canada), Rejuveron Senescence Therapeutics (Switzerland & Spain), Rejuveron Vascular Therapeutics (Switzerland), Rejuveron Telomere Therapeutics (Switzerland), Rejuvenate BioMed (Belgium) and Boost Neuroscience (US).

Co-founded in 2019 by entrepreneurial scientist, Matthias Steger, and visionary investor, Christian Angermayer, Rejuveron has state-of-the-art incubator laboratory facilities and offices at its headquarters in Zürich’s Bio-Technopark (Switzerland) as well as program teams located in the USA, Canada, Spain and Belgium.